Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS‐CoV‐2: AGILE CST‐3a/b

Le résumé fourni par la source

findings, we have found that EC50 values increased with delayed treatment of the three drugs.This indicates that anti-CMV potency depends on treatment initiation time as well as the infection age of the cell culture.Overall, we have observed that dosing delays affect pharmacodynamic outcomes differently for different drugs.We have found that ganciclovir has the most potent effect in suppressing viral load burden among other drugs when treatment is initiated with delay.Conclusion: Our in vitro data suggest that the dose-response effect on antiviral activity for anti-CMV drugs depends on treatment initiation time.Delayed treatment is consistently found associated with higher EC50 values.These findings suggest that potency decreases with infection age.Additionally, the impact of dosing delays on pharmacodynamic outcomes varied between different drugs.The PK/PD of these drugs is thus different and will be further investigated in a dynamic hollow fibre infection model.In conclusion, our overall findings suggest that timing of drug administration is crucial for improving clinical outcomes in CMV treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.